infliximab

Drug Overview

Infliximab is a highly specialized medication classified as a biologic therapy. It belongs to a group of medicines known as Tumor Necrosis Factor-alpha (TNF-alpha) inhibitors. Acting as a “Targeted Therapy,” infliximab is carefully engineered to work on specific parts of the immune system to stop severe inflammation. While it is primarily used to treat chronic autoimmune diseases, it also plays a vital role in cancer care by managing the serious side effects of modern cancer immunotherapies. Because it is a large and complex biologic molecule, it cannot be taken as a simple pill and must be delivered directly into the body.

• Generic Name: Infliximab (Biosimilars include infliximab-dyyb, infliximab-abda, and infliximab-axxq).
• US Brand Names: Remicade, Inflectra, Renflexis, Avsola, Zymfentra.
• Drug Class: TNF-alpha Inhibitor / Biologic / Monoclonal Antibody.
• Route of Administration: Most commonly given as an Intravenous (IV) infusion directly into a vein. A Subcutaneous (SC) injection form is also available for specific maintenance therapies.
• FDA Approval Status: Fully FDA-approved for standard public use in a variety of specific autoimmune conditions.
  
  Find expert information on infliximab immunotherapy applications. Trust our leading medical hospital for specialized patient treatments.
  
  

What Is It and How Does It Work? (Mechanism of Action)

Infliximab is a type of “Smart Drug” called a monoclonal antibody. To understand how it works, we must look at how the body’s immune system communicates. When the body detects a threat, immune cells release a signaling protein called Tumor Necrosis Factor-alpha (TNF-alpha). In a healthy body, TNF-alpha helps fight infections. However, in autoimmune diseases, the body produces way too much TNF-alpha. This leads to chronic, heavy inflammation that damages healthy tissues and organs.

At the molecular level, infliximab works as a highly specific blocker to stop this damage:

• Targeting the Protein: Once infliximab enters the bloodstream, it actively searches for both free-floating TNF-alpha proteins and those attached to the surface of cells.
• Blocking the Receptors: By locking tightly onto the TNF-alpha protein, infliximab stops it from attaching to its natural landing pads (known as TNFR1 and TNFR2 receptors) on the surface of healthy cells.
• Stopping the Inflammation Signal: Because the TNF-alpha cannot connect to its receptor, it cannot activate the NF-κB pathway. This pathway is essentially a genetic switch that tells the cell to create more inflammation. Infliximab keeps this switch turned off.
• Promoting Cell Normalcy: Infliximab also triggers apoptosis (programmed cell death) in the overactive immune cells that are causing the disease. By doing this, it drastically reduces the release of other inflammatory chemicals (like IL-1 and IL-6) and stops special enzymes from breaking down healthy organ tissue.

FDA Approved Clinical Indications

While infliximab is heavily relied upon in major cancer centers, its official FDA approvals are primarily for autoimmune disorders.

Non-oncological Uses:

• Crohn’s Disease (Adult and Pediatric)
• Ulcerative Colitis (Adult and Pediatric)
• Rheumatoid Arthritis (used in combination with methotrexate)
• Ankylosing Spondylitis
• Psoriatic Arthritis
• Severe Plaque Psoriasis

Oncological Uses (Cancer Care):

• Immunotherapy Toxicity Management: While infliximab is not a traditional chemotherapy drug that kills cancer cells, it is heavily used in oncology to treat severe immune-related adverse events (irAEs). When cancer patients receive modern immune checkpoint inhibitors (like nivolumab or ipilimumab), their immune system can become overactive and attack healthy organs. Infliximab is a standard-of-care medical guideline treatment for managing severe, steroid-resistant immunotherapy-induced colitis (severe colon inflammation) and is occasionally used for lung inflammation (pneumonitis).

Dosage and Administration Protocols

Because infliximab is a powerful biologic, the dose is usually calculated based on the patient’s exact body weight. Treatment is divided into a starting “induction” phase to build up the drug in the body, followed by a long-term “maintenance” phase.

Clinical Efficacy and Research Results

Recent clinical research spanning from 2020 to 2025 confirms that infliximab is highly effective for both chronic autoimmune diseases and cancer-related immune complications.

• Treating Autoimmune Disease: A major 2025 medical analysis comparing infliximab to other biologic treatments showed excellent results. For patients with Crohn’s Disease, 64% of patients receiving infliximab achieved long-term clinical remission at one year, which was significantly higher than alternative targeted therapies. In ulcerative colitis, patients taking infliximab showed a 1.52 times higher likelihood of achieving long-term healing compared to standard treatments.
• Cancer Immunotherapy Support: A large 2024 clinical study looked at cancer patients who developed severe immune complications (like severe colitis) from their cancer treatments. Within 3 months of receiving infliximab, 71% of patients successfully responded, meaning their dangerous side effects were resolved. Importantly, the study proved that using infliximab to calm the immune system did not lower the effectiveness of the patient’s original cancer treatment, preserving their overall survival rates.

Safety Profile and Side Effects

Because infliximab lowers the immune system’s overall ability to fight, it comes with strict and highly important safety warnings.

BLACK BOX WARNING:

• Risk of Serious Infections: Patients treated with infliximab are at an increased risk for developing severe infections that may lead to hospitalization or death. This includes tuberculosis (TB), severe bacterial infections, and invasive fungal infections (like histoplasmosis).
• Risk of Malignancy: Lymphoma and other cancers have been reported in children and young adults treated with TNF blockers. A rare and often fatal type of cancer called hepatosplenic T-cell lymphoma has occurred, mostly in teenage and young adult males being treated for inflammatory bowel disease.

Common Side Effects (>10%):

• Upper respiratory infections (such as sinus infections or sore throats).
• Headaches and a persistent cough.
• Stomach pain or nausea.
• Infusion reactions (mild rash, itching, or redness during the IV drip).

Serious Adverse Events:

• Severe allergic reactions (anaphylaxis) happening during or immediately after the infusion.
• New or worsening heart failure.
• Liver damage (hepatotoxicity).
• Nervous system problems (such as sudden numbness, tingling, or changes in vision).

Management Strategies:

• If a patient experiences a reaction during the IV drip, the medical team will immediately slow down or stop the infusion. They may give quick-acting medicines like acetaminophen, antihistamines, or steroids to safely calm the reaction.
• Patients with any suspected active infection will have their infliximab treatment paused immediately until the infection is fully cured.

Connection to Stem Cell and Regenerative Medicine

While infliximab is not a stem cell therapy itself, it has a direct and important connection to the rapidly advancing field of Immunotherapy. In modern regenerative medicine and cancer care, doctors use advanced treatments (like CAR-T cell therapy or checkpoint inhibitors) to forcefully wake up the patient’s immune system. However, this awakened immune system can sometimes become too aggressive, causing severe, life-threatening inflammation in healthy tissues. Infliximab acts as an essential “rescue” medicine in these modern protocols. By serving as a precise off-switch for TNF-alpha, infliximab allows doctors to safely push the boundaries of immunotherapy, knowing they have a reliable and fast-acting tool to rescue the patient if their immune system becomes dangerously overactive.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• Tuberculosis (TB) Test: A strict skin test or blood test is required to ensure the patient does not have hidden TB before starting.
• Hepatitis B Screening: A blood test to check for the Hepatitis B virus, as the drug can cause a dormant virus to wake up.
• Baseline Blood Work: Standard tests to check complete blood counts, heart health, and liver function.

Precautions During Treatment:

• Patients will be monitored closely in the clinic for at least one to two hours after the IV drip finishes to ensure no delayed allergic reactions happen.
• Because the immune system will be lowered, patients must be highly careful about washing their hands and avoiding sick individuals.

“Do’s and Don’ts” List:

• DO tell your doctor immediately if you develop a fever, cough, warm or red skin, or any signs of an infection.
• DO make sure you are fully up to date with non-live vaccines (like the standard flu shot) before starting your therapy.
• DO report any signs of heart problems right away, such as sudden weight gain, shortness of breath, or swelling in your ankles.
• DON’T receive any “live” vaccines (such as the MMR or yellow fever vaccine) while you are actively receiving infliximab treatment.
• DON’T ignore persistent stomach pain, extreme tiredness, or yellowing of your skin or eyes; report these to your healthcare team immediately.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Infliximab is a potent prescription medication with significant risks and benefits. Treatment protocols vary greatly depending on the individual patient and their specific underlying condition. Always consult with a qualified healthcare professional, rheumatologist, gastroenterologist, or your treating oncologist regarding diagnosis, treatment options, safety profiles, and your personal eligibility for this medication.